According to this classification, in our study, TLR10 was expressed at significantly higher levels in the CD19+CD5+ subset in the RA subjects than in the HCs, while there was a small decrease in TLR10 expression in the CD19+CD5− subset in the RA subjects, consistent with our above conclusion that B cell subsets with proinflammatory properties show decreased TLR10 expression and tend to be more inflammatory, while B cell subsets with immunomodulatory properties show increased TLR10 expression and act to inhibit inflammation. The gene discussed is TLR10; the disease is rheumatoid arthritis.